Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $470.13, moving +2.54% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 0.06% for the ...

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (VRTX-2.24%).Compared to the S&P 500 index, which is down about 16 ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts ...

Vertex Pharmaceuticals Inc VRTX is entering earnings week with some serious anticipation — and a bit of heartburn. The stock had a solid run in 2025, up nearly 20% year-to-date and 21% over the ...

As these one-time costs subside, analysts see Vertex earning $18.78/share in fiscal 2025, with the stock trading for approximately 24.1x 2025 earnings. This is more or less in line with the ...

Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment. It’s the first new class of pain treatment approved in more than 20 years, Vertex says.

3 Reasons to Buy Vertex Pharmaceuticals Stock Like There's No Tomorrow. 3 Top Growth Stocks to Buy in the Second Half of 2025. This Stock Just Dropped by 12% in 1 Day.

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday ...